Asian Pacific Journal of Cancer Prevention最新文献

{"title":"Awareness of Cancer Among Japanese Junior and Senior High School Students and Relevant Factors.","authors":"Yoko Minamiguchi, Kumi Suzuki, Yasuhiro Tsuda, Yuko Tomari, Ikue Shino, Masako Yamanaka, Naoko Hayashi, Eiko Yamauchi, Akiko Fukawa, Tomoki Doi, Yasuhito Fujisaka","doi":"10.31557/APJCP.2026.27.6.2345","DOIUrl":"10.31557/APJCP.2026.27.6.2345","url":null,"abstract":"<p><strong>Objective: </strong>The purpose of this study was to clarify cancer awareness among Japanese youths, identify relevant factors, and gain insight into effective educational interventions to prevent cancer and promote early detection in youths.</p><p><strong>Methods: </strong>We conducted an anonymous, fact-finding questionnaire survey via the Internet, covering three modules of the Cancer Awareness Measure (cancer risk factors, cancer warning signs, and barriers to help-seeking), along with individual and environmental factors. Descriptive statistics were generated, and chi-squared tests and logistic regression analyses were performed to clarify the associations between cancer awareness and individual and environmental factors.</p><p><strong>Results: </strong>In total, 612 junior and senior high school students were enrolled. The median (interquartile range) total score was 7 (4-10) for cancer risk factors, 0 (0-5) for cancer warning signs, and 4 (2-7) for barriers to help-seeking. Less than half of the students correctly recognized risk factors specific to cancer, such as human papillomavirus, hepatitis B virus, and hepatitis C virus infections. As for barriers to help-seeking, many students pointed to emotional barriers such as fear (62.9%). Other major barriers to help-seeking were female gender (odds ratio [OR]=2.80, 95% confidence interval [CI]: 1.73, 4.53, p < 0.001), conversations with parents about cancer (OR=2.28, 95% CI: 1.28, 4.08, p = 0.005), and awareness of cancer warning signs (OR=1.04, 95% CI: 1.04, 1.81, p = 0.003).</p><p><strong>Conclusion: </strong>Japanese adolescents do not have sufficient awareness of cancer. In cancer education, it is necessary to clearly highlight cancer-specific risk factors and warning signs in an easy-to-understand manner, explain the importance of early detection, and consider the content of cancer-related conversations between children and parents.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 6","pages":"2345-2354"},"PeriodicalIF":0.0,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148609845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Androgen Receptor and EGFR in Carcinoma ex Pleomorphic Adenoma: A Systematic Review and Meta- Analysis.","authors":"Ija Mayuek, Abikshyeet Panda, Harish Kumar, Lipsa Bhuyan, Kailash Chandra Dash, Pallavi Mishra","doi":"10.31557/APJCP.2026.27.7.2407","DOIUrl":"10.31557/APJCP.2026.27.7.2407","url":null,"abstract":"<p><strong>Background: </strong>Carcinoma ex pleomorphic adenoma (Ca-ex-PA) is a rare salivary gland malignancy with limited therapeutic options. Molecular targets such as androgen receptor (AR) and epidermal growth factor receptor (EGFR) may offer prognostic and therapeutic value.</p><p><strong>Objective: </strong>To systematically review the current literature regarding the role of AR and EGFR in the pathogenesis, progression, and management of Ca-ex-PA.</p><p><strong>Methods: </strong>The review adhered to Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines and was registered in PROSPERO with the registration number CRD420251118578. A systematic literature search was conducted in PubMed, Scopus, Google Scholar, and EBSCOhost databases for studies published upto January, 2026. Inclusion criteria were studies assessing AR and/or EGFR in Ca-ex-PA using immunohistochemistry, molecular techniques, or clinical data. Risk of bias was assessed using the ROBINS tool, and pooled prevalence estimates were calculated using random-effects models.</p><p><strong>Results: </strong>Eighteen studies were included for qualitative synthesis and meta-analysis. AR expression was found to be highly prevalent in CXPA, particularly in cases with salivary duct carcinoma components, while benign pleomorphic adenoma consistently showed minimal or absent AR expression. EGFR expression demonstrated marked heterogeneity across studies but was generally higher in malignant components compared with benign areas. Overall, included studies exhibited moderate to high risk of bias, mainly related to confounding, post-exposure interventions, and selective reporting.</p><p><strong>Conclusion: </strong>AR is a consistently expressed and biologically relevant biomarker in CXPA, supporting its diagnostic and potential therapeutic role. EGFR expression reflects molecular heterogeneity and may contribute to malignant progression, although its clinical utility remains uncertain. Standardized biomarker assessment and prospective studies are required to strengthen evidence and guide targeted therapy in CXPA.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 7","pages":"2407-2416"},"PeriodicalIF":0.0,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148609838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated Transcriptomic Analysis Identifies Overlapping Gene Networks Between Breast Cancer Stem Cells and Paclitaxel-Primed Mesenchymal Stem Cell-Activated T Cells as Potential Immunotherapeutic Targets.","authors":"Yan Wisnu Prajoko, Dedy Hermansyah, Tri Widiandani, Nur Dina Amalina","doi":"10.31557/APJCP.2026.27.7.2601","DOIUrl":"10.31557/APJCP.2026.27.7.2601","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer stem cells (BCSCs) are responsible for chemotherapy resistance, metastasis, and tumor recurrence. Paclitaxel-primed mesenchymal stem cells (MSCs) can activate T cells, offering a novel immunotherapeutic approach. However, the molecular mechanisms underlying BCSC-immune interactions remain poorly understood.</p><p><strong>Objective: </strong>To identify overlapping gene networks between BCSCs, paclitaxel-treated cells, activated T cells, and paclitaxel-primed MSCs, and to validate their functional relevance in targeting BCSCs.</p><p><strong>Methods: </strong>Comparative transcriptomic analysis was performed using data from TCGA to identify genes co-expressed across BCSCs, paclitaxel-treated cells, activated T cells, and MSCs. Protein-protein interaction network analysis, Gene Ontology (GO) enrichment, and KEGG pathway mapping were conducted using STRING-DB, DAVID, and cBioPortal. Mutation analysis and survival correlations were assessed across 151 breast cancer samples. Experimental validation was performed using MTT viability assays and qRT-PCR in metastatic breast cancer cells treated with paclitaxel, activated T cell-conditioned medium, and MSC-derived factors.</p><p><strong>Results: </strong>We identified 158 genes co-expressed across all four conditions, forming a highly interconnected PPI network (136 nodes, 524 edges). Network centrality analysis revealed TP53, AKT1, and STAT3 as top hub genes. GO enrichment analysis demonstrated significant involvement in epithelial cell proliferation, stress responses, and transcriptional regulation. KEGG pathway analysis revealed enrichment in the PI3K-Akt signaling pathway, the PD-L1/PD-1 checkpoint pathway, and Th1/Th2 differentiation. TP53 was the most frequently mutated gene (77.5%), which correlated with a poor prognosis. Experimental validation demonstrated that combined paclitaxel and activated T cell treatment reduced BCSC viability by 75%, upregulated TP53 expression, and suppressed PIK3CA expression by 85%.</p><p><strong>Conclusion: </strong>This study reveals critical molecular networks connecting BCSCs and immune activation, identifying TP53, AKT1, and STAT3 as central therapeutic targets. Paclitaxel-primed MSC-activated T cells synergize with chemotherapy to suppress BCSC viability by modulating the TP53 and PIK3CA pathways, providing a mechanistic rationale for combinatorial immunotherapy in breast cancer.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 7","pages":"2601-2614"},"PeriodicalIF":0.0,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148610226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dosimetric Comparison of Three-dimensional Conformal Radiation Therapy (3D-CRT) vs Volumetric Modulated Arc Therapy (VMAT) for Primary Malignant Brain Tumors.","authors":"Pragnahitha Neerudu, Arpitha S, Chandramouli Ramalingam, Kesavan Murugesan, Naga Sai Divya Kari, Thirumal M, Ajay Kumar Kondeti","doi":"10.31557/APJCP.2026.27.7.2643","DOIUrl":"10.31557/APJCP.2026.27.7.2643","url":null,"abstract":"<p><strong>Background: </strong>Advances in radiotherapy planning have led to better dose delivery and protection of organs at risk (OAR) in malignant brain tumors. Though three-dimensional conformal radiotherapy (3D-CRT) is still commonly used, Volumetric modulated arc therapy (VMAT) delivers highly precise doses with dynamic adjustments. This study compares dosimetric differences prospectively between 3D-CRT and VMAT in primary malignant brain tumors.</p><p><strong>Methods: </strong>Fifty (50) patients with confirmed malignant primary brain tumors who received postoperative or definitive radiotherapy were assessed. Each patient had CT simulations, target and OAR contouring, and two distinct plans: 3D-CRT and VMAT using 6 MV photons. Treatment was delivered as per VMAT planning. The dosimetric endpoints included PTV coverage (D2%, D50%, D98%), conformity index (CI), homogeneity index (HI), and OAR doses (optic nerves, optic chiasm, brainstem, cochlea, retina, lens, pituitary, and spinal cord).</p><p><strong>Results: </strong>VMAT delivered significantly lower doses to some OARs compared to 3D-CRT. The Dmax to the right and left optic nerves was significantly lower with VMAT (24.77 Gy vs. 32.34 Gy, p=0.002; 27.35 Gy vs. 32.86 Gy, p=0.032). For the optic chiasm, both the Dmax and Dmean doses were significantly lower with VMAT (31.28 Gy vs. 36.32 Gy, p=0.036; 24.27 Gy vs. 30.77 Gy, p=0.019). The Dmean  for the right cochlea was greatly reduced (7.27 Gy vs. 15.97 Gy, p=0.007). Differences in doses to the brainstem, pituitary, retina, and lens were minimal and not statistically significant. The PTV metrics (D2%, D50%, D98%) showed no significant differences between the techniques. The conformity index was acceptable for both plans (VMAT 0.903; 3D-CRT 1.089). Homogeneity indices were similar.</p><p><strong>Conclusion: </strong>VMAT offers better sparing of several critical OARs, such as the optic pathways and cochleae, while maintaining similar PTV coverage compared to 3D-CRT. Both techniques meet acceptable dose limits, but VMAT may be preferred for tumors near sensitive structures.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 7","pages":"2643-2651"},"PeriodicalIF":0.0,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148610284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and GenBank Registration of Two Novel Bloodstream Bacterial Strains from Oncology Patients: Escherichia Coli OncoEval 1 and Pseudomonas Aeruginosa OncoEval 2.","authors":"Bassam Abdul Rasool Hassan, Watheq Mohammed Al-Jewari, Ali Haider Mohammed, Ahmed Zuhair Abdulhameed Alsammarraie, Mohammed Kamil Al Qayyim, Abu Bakar Abdul Majeed, Muhamad Faiz Othman, Musaab Kadhim Alabboodi","doi":"10.31557/APJCP.2026.27.7.2359","DOIUrl":"10.31557/APJCP.2026.27.7.2359","url":null,"abstract":"<p><strong>Objective: </strong>Bloodstream infections are a significant complication in cancer patients and play an important role in morbidity and mortality, especially in immunocompromised populations. It is crucial that clinically derived bacterial strains be molecularly documented to aid infection surveillance and future translational research in oncology practice.</p><p><strong>Methods: </strong>This brief communication describes the identification and National Center for Biotechnology Information (NCBI) GenBank registration of two bacterial strains isolated from bloodstream infections in oncology patients. Partial 16S ribosomal RNA gene sequencing was used for molecular identification.</p><p><strong>Results: </strong>One isolate was identified as Escherichia coli strain OncoEval 1, and the second as Pseudomonas aeruginosa strain OncoEval 2. Validated and quality-screened sequences of both were deposited in the GenBank database to provide public genomic references derived from cancer-associated bloodstream infections.</p><p><strong>Conclusion: </strong>The registration of these strains broadens the molecular resource base for pathogens isolated from oncology patients and drives continued studies in infection surveillance and research in the setting of cancer care.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 7","pages":"2359-2362"},"PeriodicalIF":0.0,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148610287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling Optimal Cervical Cancer Screening Age Range: Study of HPV Infection Among 75,719 Women in Indonesia's Metropolitan Regions (2012 - 2022).","authors":"Tofan Widya Utami, Laila Nuranna, Gatot Purwoto, Arisda Oktalia, Raysa Irzami, Andi Utama, Eva Suarthana","doi":"10.31557/APJCP.2026.27.7.2541","DOIUrl":"10.31557/APJCP.2026.27.7.2541","url":null,"abstract":"<p><strong>Objectives: </strong>Human papillomavirus (HPV) is the primary cause of cervical cancer, a global health crisis. Indonesia is placed as having the highest cervical cancer incidence and fatality in Southeast Asia. Currently, under the National Cervical Cancer Elimination (NCCE) plan, Indonesia has extended HPV DNA-based screening from 30-50 to 30-69 years old. However, various factors can lead to inadequate virus clearance in younger populations, and Indonesia has not yet had a large-scale analysis of age-specific HPV infection reports, leaving the ideal screening age uncertain. Therefore, this study aims to investigate age-specific HPV prevalence in Indonesia to inform the optimal age range for cervical cancer screening.</p><p><strong>Methods: </strong>In this retrospective cross-sectional study, 75,719 subjects' data were utilized from all metropolitan regions in Indonesia from 2012-2020, who were tested with HPV DNA using PCR (SPF10-DEIA-LiPA25) and hybridization. The data were then analyzed by age and HPV genotype using IBM SPSS 27.0.</p><p><strong>Results: </strong>12.62% of 75,719 women aged 13-75 are HPV-positive. Women aged 30-39 (39.56%) and 40-49 (21.1%) had the highest infection rates, followed by 25-29 (18.9%) and those below 25 years (8.8%). This contrasts with the infection rates of women aged 60-65 (1.5%) and 66-69 (0.6%). Across all age categories, HPV52, HPV16, and HPV58 were the most prevalent high-risk genotypes, with substantial variations in infection rates (p <0.001). High-risk HPV outnumbered low-risk HPV in all age categories.</p><p><strong>Conclusion: </strong>HPV-positive prevalence in the younger population, particularly among those aged 25-29, is frequent in Indonesia. After age 65, HPV-positive cases drop significantly. Several variables contribute to this. This study recommends adjusting cervical cancer screening to Indonesian women aged 25-65.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 7","pages":"2541-2548"},"PeriodicalIF":0.0,"publicationDate":"2026-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148610195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Hybrid Perception Network for Accurate and Interpretable Brain Tumor Classification Using Multi-Modal Imaging.","authors":"Hamad D Al-Sharari","doi":"10.31557/APJCP.2026.27.7.2525","DOIUrl":"10.31557/APJCP.2026.27.7.2525","url":null,"abstract":"<p><strong>Objective: </strong>Accurate classification of brain tumors is of utmost importance in early diagnosis and treatment, which can be further enhanced through advanced deep learning techniques. This work introduces HyPerNet-a Hybrid Perception Network for brain tumor classification that integrates cutting-edge methods to maximize classification accuracy, interpretability, and efficiency. HyPerNet leverages multi-modal fusion, combining Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Positron Emission Tomography (PET) scans to extract complementary information from different imaging modalities.</p><p><strong>Methods: </strong>A dynamic attention mechanism adapts to image complexity, improving performance under noisy and artifact-laden conditions. The architecture incorporates explainable AI components using Grad-CAM for clinical interpretability, along with 3D convolutional neural networks for volumetric feature learning. Hybrid feature extraction, integrating Convolutional Neural Networks (CNNs) with graph neural networks (GNNs), enables the model to capture both local and relational tumor characteristics. Domain adaptation via transfer learning allows the model to generalize across diverse datasets, improving robustness.</p><p><strong>Result: </strong>In experiments conducted on a benchmark dataset of 8,256 images, HyPerNet achieved a classification accuracy of 97.14%, precision of 97.09%, recall of 97.09%, F1-score of 97.09%, and specificity of 98.9%, outperforming state-of-the-art models such as DenseNet121, ResNet101, and MobileNetV3. Notably, HyPerNet attains these results with only 1.66 million parameters, making it highly efficient for deployment on mobile and edge devices.</p><p><strong>Conclusion: </strong>These findings establish HyPerNet as a reliable, interpretable, and computationally efficient solution for clinical brain tumor classification.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 7","pages":"2525-2534"},"PeriodicalIF":0.0,"publicationDate":"2026-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148609830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Squamous Cell Carcinoma: A New Era in Molecular Mechanisms and Emerging Targeted Therapies.","authors":"Bhavana Harendra, Ashwini P, Kavana C P, Abhigna Nagaraj, Chandan Dharmashekar, Shuaib Pasha, Devanand D, Shivaprasad Kollur, Raghavendr G Amachawadi, Chandan Shivamallu","doi":"10.31557/APJCP.2026.27.7.2379","DOIUrl":"10.31557/APJCP.2026.27.7.2379","url":null,"abstract":"<p><strong>Objective: </strong>Oral squamous cell carcinoma (OSCC), the most common oral cancer, presents a clinical challenge due to its complex tumor microenvironment (TME), dysregulated pathways, and poor prognosis. Current methods of diagnosing OSCC use liquid biopsy technologies (ctDNA/microRNAs/exosomes) instead of relying solely on traditional methods such as open surgical biopsy. Liquid biopsy technologies provide non-invasive ways to detect and monitor OSCC in early stages, compared with traditional open surgical biopsy methods. Treatment of OSCC currently relies on chemotherapeutics (cisplatin/5-FU), radiotherapy, and targeted agents (cetuximab). However, resistance is acquired due to TME remodelling (tumor microenvironment) and/or due to epithelial-mesenchymal transition (EMT) through processes such as ABC transporter efflux. This review elucidates key molecular mechanisms, including PD-L1-mediated immune evasion, PI3K/AKT/mTOR hyperactivation, EGFR overexpression, and NF-κB-driven inflammation, which promote proliferation, metastasis, and therapy resistance. One area of study involves the use of nanotechnology to convert phytocompounds (medicinal plants) into therapeutic agents by embedding phytocompounds into nanoparticles created using green synthesis techniques. EPR (Enhanced Permeability and Retention), ligand functionalization for OSCC targeting, improved bioavailability, and reduced toxicity are all advantages that the aforementioned systems provide, offering an opportunity to synergistically develop new therapies with chemotherapeutics for overcoming resistance.</p><p><strong>Conclusion: </strong>While numerous preclinical studies demonstrate that these newly developed therapies show increased efficacy compared with current therapy options, further work is needed in areas such as standardization, scaling, and clinical translation. As such, the importance of developing pathway-informed diagnostic tests and developing therapies that exploit pathway-specific activity with phytocompounds is emphasized. In addition, large-scale studies should be considered to evaluate the effectiveness of a pathway-informed approach in assessing and differentiating OSCC and personalized therapy strategies, to improve OSCC survival outcomes.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 7","pages":"2379-2391"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148609517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Presentation and Survival of Children with Retinoblastoma Treated at the National Eye Centre in Indonesia.","authors":"Anne Susanty, Primawita Oktarima, Friska Mardianty, Kanyawati Maliani, Angga Kartiwa, Adji Kusumadjati, Widia Noviyanti, Pujani Utami, Nindi Dwi Leoni, Dika Maulana, Karen Fischhuber, Petra Ketteler","doi":"10.31557/APJCP.2026.27.7.2549","DOIUrl":"10.31557/APJCP.2026.27.7.2549","url":null,"abstract":"<p><strong>Background: </strong>Retinoblastoma is a malignant ocular tumor in children. Patient characteristics differ between low- and middle-income countries and high-income countries. This study analyzes the clinical presentation and survival rates of patients with retinoblastoma at the National Eye Center (NEC) in Indonesia, a middle-income country.</p><p><strong>Methods: </strong>Clinical data of all children diagnosed with retinoblastoma at NEC between 2012 and 2021 were retrospectively analyzed.</p><p><strong>Results: </strong>In 10 years, 395 patients with retinoblastoma were diagnosed and treated at NEC. The number of diagnoses increased from 2012 to 2019, but declined during the COVID-19 pandemic. Most patients were diagnosed under 5 years of age. The most common sign was leukocoria (77.5%), followed by proptosis (14.0%). Proptosis was even more common in children from remote areas of Indonesia (20.0%). At NEC, 73.4% had unilateral and 26.6% bilateral retinoblastoma. Patients with bilateral retinoblastoma were statistically noticeably younger at diagnosis than unilateral retinoblastoma (unilateral: 27 months; bilateral 21 months; p<0.001). In patients diagnosed between 2017 and 2021, overt extraocular retinoblastoma (IRSS III and IV) was detected in 16.1% while only 5.4% of patients presented with IRSS 0/I at diagnosis. The 3-year overall survival rate for patients diagnosed between 2017 and 2021 was 53.5% (95%-CI: [43.1%, 66.4%]).</p><p><strong>Conclusion: </strong>In Indonesia extraocular disease at diagnosis is common contributing to low survival rates. To address this, early detection programs, standardized referral pathways, and treatment guidelines have been implemented. These efforts aim to improve survival outcomes and bring them closer in line with those of other middle-income countries.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 7","pages":"2549-2556"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148610119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Validation of a One-Step Multiplex RT-qPCR Assay for BCR-ABL1 Transcript Detection and Monitoring in Moroccan Chronic Myeloid Leukemia Patients.","authors":"Abdenacer Benchrifa, Basma Albanyahyati, Mounyr Balouiri, Hicham El Hadi, Youssef Bakri, Kamal Doghmi, Abdeladim Moumen","doi":"10.31557/APJCP.2026.27.7.2481","DOIUrl":"10.31557/APJCP.2026.27.7.2481","url":null,"abstract":"<p><strong>Objective: </strong>Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion gene. Molecular monitoring of this transcript is essential for patient management. However, the high cost of imported assays limits access to regular monitoring in Morocco.</p><p><strong>Methods: </strong>We developed and validated a cost-effective one-step multiplex RT-qPCR assay that simultaneously detects BCR-ABL1 and ABL1 transcripts in peripheral blood mononuclear cells. Samples from 63 Moroccan CML patients were analyzed and compared with the GeneXpert system.</p><p><strong>Result: </strong>The assay showed efficiencies above 95% and R2 ≥ 0.99 for both targets. BCR-ABL1/ABL1 ratios correlated strongly with GeneXpert (r = 0.93, p < 0.001) and showed 86% overall agreement.</p><p><strong>Conclusion: </strong>This locally developed assay is a reliable and affordable alternative for routine BCR-ABL1 detection and monitoring, improving access to molecular testing in resource-limited settings.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 7","pages":"2481-2489"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148610232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}